Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam

April 20, 2011 By Bio-Medicine.Org

SAN DIEGO, April 20, 2011 /PRNewswire/ — Neurelis, Inc. today
announced the completion of subject dosing in a randomized
crossover study assessing diazepam pharmacokinetics and
bioavailability after administration of two proprietary
formulations of intranasal diazepam and intravenous injection.
Through the collaboration with the University of Minnesota and
James Cloyd, PharmD; Neurelis has partnered with the leading
experts in clinical research of the nasal delivery of
benzodiazepines.  Results from this important study are
expected in June.

“We are pleased to work with Dr. Cloyd and the University of
Minnesota to complete dosing in the first human trial of our unique
nasally administered formulations of diazepam,” stated David Hale,
Chairman.  “Neurelis has incorporated proprietary technologies
to develop intranasal diazepam formulations that can be delivered
with a standard sprayer to patients experiencing acute breakthrough
seizures.  These intranasal product formulations seek to
address the need for a convenient and effective therapy that could
help reduce acute breakthrough seizures and avoid the need for
costly emergency room visits.”

Intranasal diazepam is being developed for the management of
patients who require intermittent use of diazepam to control bouts
of acute breakthrough seizure activity. There are over 2.7 million
people with epilepsy in the United States.  It is estimated
that between 30% to 40% of these patients are uncontrolled on oral
therapy and are at-risk for acute breakthrough seizures.
 Studies have shown that prolonged or repetitive seizures can
cause neurological damage and dramatically increase the risk of
changes in neuropsychological function or even death.

Presently, there is only one product approved for the treatment
of acute repetitive seizures outside of the acute care setting,
which is a rectally administered formulation of diazepam called
Diastat®.  Because of its rect

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech